Address: 150 Beach Road #31-00 Gateway West, Singapore 189720 ,Singapore
Tel: (65) 6508 8400
Web: http://www.msd-singapore.com/about-us/home.html
The Asia Pacific is a leading growth driver for MSD within the Emerging Markets. Headquartered in Singapore, MSD’s Asia Pacific operations span thirteen diverse geographies encompassing Australia, China, Hong Kong, India, Indonesia, the Republic of Korea, Malaysia, New Zealand, Philippines, Singapore, Taiwan, Thailand, and Vietnam.
MSD has been present in the Asia Pacific for some 60 years and currently employs about 17,000 people.
Over the coming decade, most of the world’s pharmaceutical growth will come from the Emerging Markets, including the Asia Pacific. Driving performance in these high-growth markets is a priority for MSD, and their vision for the Asia Pacific focuses on the following strategies:
Core BrandsAchieve market leadership
New Product LaunchesAccelerate time to market
Ensure successful product launches
Diversified PortfolioGrow their diversified products through new, innovative business models
Innovative Branded GenericsDevelop new country strategies and business models to launch and commercialize innovative branded generics.
Innovative drugs
MSD’s Ashish Pal describes how he led the Singapore, Malaysia, and Brunei cluster through a challenging 2020; the importance of leveraging learnings from the past year to create a more…
Simranjit Singh highlights Guardant Health’s role in the global precision oncology landscape and how the company leverages its proprietary blood tests, vast data sets, and advanced analytics across the huge…
John Baby of home rehabilitation device start-up WO:EX outlines how his firm’s products differ from others on the market through their multifunctionality, its expansion plans in Asia and Australia, and…
Dr Varun Sethi outlines some of the most important trends in ASEAN healthcare today and how DKSH, as a historic business services provider, is adapting its offering to meet them.…
Since 2000, when Singapore first positioned biomedical research as the fourth pillar of the country’s economy, government funding towards innovative life sciences start-ups and spin-offs has dramatically increased. These companies…
Annie Tan highlights the strategy she laid out to navigate the BMS Singapore, Thailand and Malaysia affiliates through the COVID-19 pandemic; the opportunities and challenges of integrating the Celgene portfolio…
Kenneth Tan has been President for Asia Pacific & Japan at cancer-focused medical device player Varian since February 2019. In a recent conversation with PharmaBoardroom, Tan shared how an early…
Professor Ng Huck Hui of A*Star’s Biomedical Research Council outlines the evolution of Singapore’s science and technology research and innovation ecosystem over the past 20 years and why the country…
Dr Piers Ingram, PhD, co-founder, and CEO of Singapore-based biotech Hummingbird Bioscience, shares his motivation for establishing the company in 2015, their proprietary Rational Antibody Discovery (RAD) technology platform, and…
UPS APAC’s Bee Lim describes how the logistics giant responded to the unprecedented challenges thrown up by the COVID-19 pandemic, the trends that the pandemic has accelerated in the region,…
Cerecin’s Charles Stacey outlines the company’s progress in expanding its lead asset into migraine and infantile spasms, how its funding strategy has evolved, why Singapore is still a logical base,…
Clarence Ngui describes how global orthopaedic product giant Zimmer Biomet has pivoted in APAC in response to the COVID-19 pandemic; how medical education needs differ across the vast APAC region;…
Asia-Pacific, as home to 50 percent of the world’s new cancer cases each year and with deaths caused by cancer expected to increase by 36 percent by 2030, has a…
See our Cookie Privacy Policy Here
